The role of National Institutes of Health category IV prostatitis in accurately staging the newly diagnosed prostate cancer

Basit Öğe Kaydı
dc.authoridAglamis, Erdogan/0000-0002-7497-7573;
dc.authorwosidAglamis, Erdogan/AAA-7464-2020
dc.authorwosidceylan, cavit/JVZ-8616-2024
dc.contributor.authorAglamis, E.
dc.contributor.authorTasdemir, C.
dc.contributor.authorCeylan, C.
dc.date.accessioned2024-08-04T20:37:42Z
dc.date.available2024-08-04T20:37:42Z
dc.date.issued2013
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIt has been known that the National Institutes of Health category IV (NIH-IV) prostatitis increases the serum total prostate-specific antigen (tPSA) in patients with benign prostatic hyperplasia. However, the effect of NIH-IV prostatitis on tPSA levels, which are used for staging prostate cancer (PCa) in patients with PCa, has not been previously investigated. To evaluate the effect of NIH-IV prostatitis on the tPSA which is used for staging PCa in patients with newly diagnosed PCa. A total of 198 patients in whom PCa was detected were included in the study. Group 1 included patients with only PCa, while Group 2 included patients with prostatitis and PCa. The tPSA levels of patients in Groups 1 and 2 were compared. A total of 120 (61 %) PCa (Group 1) and 78 (39 %) PCa + NIH-IV prostatitis (Group 2) patients were identified. The tPSA levels of 70 (58 %) patients in Group 1 and 22 (28 %) patients in Group 2 were at the interval of < 20 ng/ml (the mean levels of tPSA: 11.8 +/- A 4.5 and 14.1 +/- A 3.3, respectively). The tPSA levels of 50 (42 %) patients in Group 1 and 56 (72 %) patients in Group 2 were within the range of a parts per thousand yen20 ng/ml (the mean levels of tPSA: 39.9 +/- A 31.0 and 47.0 +/- A 29.2, respectively). Within both the < 20 ng/ml range and a parts per thousand yen20 ng/ml range, the mean tPSA value in Group 2 was found to be significantly higher than that of Group 1 (p = 0.03 and 0.01, respectively). The existence of NIH-IV prostatitis together with cancer in patients with PCa significantly increases the tPSA level which is used in staging the PCa.en_US
dc.identifier.doi10.1007/s11845-013-0914-1
dc.identifier.endpage467en_US
dc.identifier.issn0021-1265
dc.identifier.issue3en_US
dc.identifier.pmid23370973en_US
dc.identifier.scopus2-s2.0-84879555607en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage463en_US
dc.identifier.urihttps://doi.org/10.1007/s11845-013-0914-1
dc.identifier.urihttps://hdl.handle.net/11616/96118
dc.identifier.volume182en_US
dc.identifier.wosWOS:000320884900026en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringer London Ltden_US
dc.relation.ispartofIrish Journal of Medical Scienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectProstate canceren_US
dc.subjectProstate-specific antigenen_US
dc.subjectProstatitisen_US
dc.subjectStageen_US
dc.subjectTreatmenten_US
dc.subjectBiopsyen_US
dc.titleThe role of National Institutes of Health category IV prostatitis in accurately staging the newly diagnosed prostate canceren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu